Ondine Biopharma Corporation announces that it has received a Health Canada license for a next-generation multi-purpose laser system that is suitable for a broad range of applications in high volume settings, such as hospitals and large institutions. This system will initially be directed towards decolonization of potentially pathogenic bacteria such as S. aureus and MRSA in the nose, as well as for the decolonization of microorganisms from other sites.
Photodisinfection utilizes photoactive agents and light sources to employ broad-spectrum disinfection across a variety of dental, medical and other applications. The Company's photodisinfection laser is expected to provide an alternative resource to antibiotics for clinicians and patients in the eradication of S. aureus and resistant 'superbugs' including MRSA. According to the Centers for Disease Control and Prevention, antibiotic resistance has become 'one of the world's most pressing public health problems.'